Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 69 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
24(42.1%)
N/A
23(40.4%)
Early Phase 1
6(10.5%)
Phase 2
4(7.0%)
57Total
Phase 1(24)
N/A(23)
Early Phase 1(6)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (69)

Showing 20 of 69 trials
NCT07546630Early Phase 1Not Yet Recruiting

Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma

Role: lead

NCT06986434Early Phase 1Not Yet Recruiting

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

Role: lead

NCT07416682Early Phase 1Not Yet Recruiting

CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms

Role: lead

NCT05517213Not ApplicableCompleted

High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma

Role: lead

NCT06834529Phase 1Recruiting

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Role: lead

NCT01898663Phase 1Recruiting

DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML

Role: lead

NCT05190042Not ApplicableCompleted

Clinical Study on Continuous Suture of Endoscopic Mucosal Defects

Role: lead

NCT05189912Not ApplicableCompleted

Clinical Study on the Application of a Specimen Retrieving Bag to Reduce the Polyp Fragmentation Rate

Role: lead

NCT06152263Unknown

LCI in Chronic Atrophic Gastritis and Early Gastric Cancer

Role: lead

NCT05574608Early Phase 1Unknown

Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Role: lead

NCT05645601Phase 1Unknown

CAR-NK Targeted CD19 for r/r B-cell Malignancies

Role: lead

NCT05214404Completed

Effect and Mechanism of Dopamine on Ulcerative Colitis

Role: lead

NCT05549284Phase 2Recruiting

Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)

Role: lead

NCT05457062Unknown

Analysis the Vocs in Upper GI Bleeding Patients

Role: lead

NCT05320497Not ApplicableUnknown

Transparent Cap-assisted SpyGlass for Biliary Stricture

Role: lead

NCT05196243Unknown

Multimodal Imaging Based on Pathological and Genomic Characteristics

Role: lead

NCT05192538Not ApplicableUnknown

A Novel Endoloop Pre-test to Treat Gastroesophageal Reflux

Role: lead

NCT05232357Early Phase 1Unknown

Endoscopic Vital Nerve Staining in Gastrointestinal Diseases

Role: lead

NCT05050630Phase 2Unknown

Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Role: lead

NCT05045911Not ApplicableUnknown

An Endoscopic Barbed-clips Suturing for Colorectal ESD

Role: lead